A. Fajardo, J.F. Linares, J.L. Martínez 

Slides:



Advertisements
Similar presentations
Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages
Advertisements

Vaccines for the elderly
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
G. Cornaglia, A. Lönnroth, M. Struelens 
Gut bacterial microbiota and obesity
R. Colodner, O. Nitzan, B. Chazan, H. Edelstein, R. Raz 
Time-trends for Gram-negative and multidrug-resistant Gram-positive bacteria associated with nosocomial infections in German intensive care units between.
Control of multidrug-resistant Gram-negative bacteria in low- and middle-income countries—high impact interventions without much resources  N. Singh,
The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram- positive bacteria  M.J. Rybak  Clinical Microbiology and Infection 
The changing nature of aminoglycoside resistance mechanisms and prevalence of newly recognized resistance mechanisms in Turkey  U. Över, D. Gür, S. Ünal,
Migrant health—a cause for concern?
Evolution of extended-spectrum β-lactamases by mutation
Genomics of epidemic pathogens
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
R. Cantón  Clinical Microbiology and Infection 
Crossing the envelope: how cephalosporins reach their targets
How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development  R. Bax  Clinical Microbiology.
Non-antibiotic strategies for sepsis
N. Clementi, F. Cappelletti, E. Criscuolo, M. Castelli, N. Mancini, R
Should standardized susceptibility testing for microbial biofilms be introduced in clinical practice?  T. Coenye, D. Goeres, F. Van Bambeke, T. Bjarnsholt 
P. Davey, C. Pagliari, A. Hayes  Clinical Microbiology and Infection 
How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach  D. Guillemot  Clinical Microbiology.
Vector control: a cornerstone in the malaria elimination campaign
Molecular mechanism of gentamicin resistance in Bartonella henselae
New Delhi metallo-beta-lactamase (NDM-1): towards a new pandemia?
Fast determination of antibiotics in whole blood
A. Oliver, A. Mena  Clinical Microbiology and Infection 
Multicenter study of the in vitro activity of cefepime in comparison with five other broad- spectrum antibiotics against clinical isolates of Gram-positive.
Training for the infectious diseases speciality in Norway
G. Höffken  Clinical Microbiology and Infection 
E.C. Böttger  Clinical Microbiology and Infection 
CMI editorial report 2011 Clinical Microbiology and Infection
Bacterial resistance—the clinical challenge
Elements of design: the knowledge on which we build
In vitro selection of antibiotic resistance in Pseudomonas aeruginosa
Levofloxacin in the treatment of ventilator-associated pneumonia
R. Bitterman, M. Paul, D. Polak, Y. Geffen 
Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin  C.G. Giske  Clinical.
Metagenomics and probiotics
The changing nature of aminoglycoside resistance mechanisms and prevalence of newly recognized resistance mechanisms in Turkey  U. Över, D. Gür, S. Ünal,
W.A. Craig  Clinical Microbiology and Infection 
S8 – S47 and O50 – O440 Clinical Microbiology and Infection
Symposia and Oral Presentations
T.M. File  Clinical Microbiology and Infection 
Systematic review of antibiotic consumption in acute care hospitals
Antibacterial drug discovery in the 21st century
Abstracts cont. Clinical Microbiology and Infection
Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci  H.L. DuPont, Z.-D. Jiang  Clinical Microbiology.
Accurate hepatitis C virus genotyping and selection of optimal therapy: lessons from a St Petersburg strain infection  E. Knops, E. Heger  Clinical Microbiology.
Vaccines for the elderly
Clinical infection services—the Leiden experience
Clinical Microbiology and Infection
Listeriosis: a resurgent foodborne infection
I. Bitar, A. Piazza  Clinical Microbiology and Infection 
N. Clementi, F. Cappelletti, E. Criscuolo, M. Castelli, N. Mancini, R
Overview of cefixime use in community-acquired infections
M.T. Pérez-Rodríguez, A. Sousa, P. Martínez-Cueto, A. Ocampo 
K. Kaier, N.T. Mutters, U. Frank  Clinical Microbiology and Infection 
The atypical pneumonias: clinical diagnosis and importance
Abstracts Clinical Microbiology and Infection
A. Ramette, J.M. Tiedje, A. Boetius 
Modelling during an emergency: the 2009 H1N1 influenza pandemic
New oral cephalosporins in pediatric community-acquired infections
B.A. Cunha  Clinical Microbiology and Infection 
J.L. Balcázar  Clinical Microbiology and Infection 
G.C. Schito  Clinical Microbiology and Infection 
Impact of antibiotic restrictions: the patient's perspective
Abstracts Clinical Microbiology and Infection
CMI readers' survey Clinical Microbiology and Infection
The future of diagnostic bacteriology
Presentation transcript:

Towards an ecological approach to antibiotics and antibiotic resistance genes  A. Fajardo, J.F. Linares, J.L. Martínez  Clinical Microbiology and Infection  Volume 15, Pages 14-16 (January 2009) DOI: 10.1111/j.1469-0691.2008.02688.x Copyright © 2009 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 1 Mechanisms of antibiotic resistance: (A) A schematic representation of a Gram-negative bacterium with two membranes. To inhibit microbial growth, an antibiotic needs to cross the cellular envelopes (I and 2), on some occasions to be modified (3) and to reach its target (4) at concentrations high enough for its effective binding. (B) Mutations in all the elements involved in this pathway can produce resistance because the membrane transporters suffer structural changes (a) or are not expressed (c), because there is a modification (e), or lack of expression of, the enzyme that activates the pre-antibiotic or because the target presents structural modifications (f) that impede the antibiotic's binding. Anti biotic-inactivating enzymes (b) and efflux pumps (d), either present in the bacterial genomes or acquired by horizontal gene transfer, also contribute greatly to antibiotic resistance. Clinical Microbiology and Infection 2009 15, 14-16DOI: (10.1111/j.1469-0691.2008.02688.x) Copyright © 2009 European Society of Clinical Infectious Diseases Terms and Conditions